JEWJITSU PEPTIDES research roundup: migraine guideline contrasts, RYGB and salt‑sensitive blood pressure, and a semi‑automated apo(a) reference method

This international guideline review compared recommendations from multiple national societies and the International Headache Society to map areas of agreement and divergence. The authors report that diagnostic criteria are based on the International Classification of Headache Disorders and that many guidelines recommend early acute treatment with analgesics and NSAIDs, while triptans are widely recommended for moderate‑to‑severe attacks. Newer drug classes such as gepants and ditans appear in more recent guidance but are noted as variably accessible depending on country. Preventive therapy is advised for frequent or disabling attacks, with commonly recommended first‑line oral agents including beta‑blockers (propranolol), antiseizure medications (topiramate, valproate) and tricyclic antidepressants (amitriptyline).

The review also summarizes differences in how calcitonin gene‑related peptide (CGRP) monoclonal antibodies and gepants are positioned across jurisdictions, noting that some guidelines (American, Japanese) place them early in preventive algorithms while others (British, French) apply restrictions. OnabotulinumtoxinA is reported as reserved for chronic migraine after failure of several oral preventives. Nonpharmacological approaches, including neuromodulation and behavioral therapies, are increasingly incorporated. The authors attribute many divergences to drug availability and insurance coverage and highlight evidence gaps for pediatric, geriatric and pregnant populations as well as for long‑term safety of newer therapies.

Limitations are noted by the authors and are inherent to guideline comparisons: recommendations reflect both the published evidence and the practical context of availability and coverage, so conclusions describe guidance documents rather than direct patient outcomes. The review calls for broader collaboration to address access and evidence gaps but does not itself generate new clinical trial data.